Showing results (31-40 of 706) with videos related to
Sort By:
Pageof 71
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2025
Muscle-Invasive Bladder Cancer: A Watershed MomentMatthew D Galsky, Leslie Ballas, Ashish M KamatExpert Review of Anticancer Therapy|December 22, 2007
Current optimal chemotherapy for advanced urothelial cancerGuru Sonpavde, Matthew D Galsky, Thomas E HutsonHematology/Oncology Clinics of North America|April 4, 2015
First-line treatment of metastatic disease: cisplatin-ineligible patientsRichard Cathomas, Maria De Santis, Matthew D GalskyFuture Oncology (London, England)|May 19, 2021
Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303Matthew D Galsky, Christopher J Hoimes, Andrea Necchi, et al.Clinical Genitourinary Cancer|June 27, 2013
Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial designGregory R Pond, Joaquim Bellmunt, Ronan Fougeray, et al.Urologic Oncology|April 20, 2012
The follicle-stimulating hormone receptor: a novel target in genitourinary malignanciesBenjamin A Gartrell, Che-kai Tsao, Matthew D GalskyJournal of the National Comprehensive Cancer Network : JNCCN|October 10, 2009
The integration of chemotherapy and surgery for bladder cancerMatthew D Galsky, Harry W Herr, Dean E BajorinFuture Oncology (London, England)|July 29, 2025
SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinomaThomas B Powles, Enrique Grande, Nimira Alimohamed, et al.European Urology|July 16, 2016
Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic FeverChe-Kai Tsao, Matthew D Galsky, William K OhEuropean Urology|January 18, 2014
Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancerChe-Kai Tsao, Matthew D Galsky, William K OhPageof 71